You are here

lymphoma

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Yahoo/Reuters

Flag link:

TG aims for accelerated approval of lymphoma candidate

TG aims for accelerated approval of lymphoma candidate

BioCentury

TG Therapeutics

Flag link:

ESMO18: Merck’s STING agonist lacks bite on its own

ESMO18: Merck’s STING agonist lacks bite on its own

Fierce Biotech

Flag link:

AbbVie's stock falls after lymphoma treatment trial data disappoints

AbbVie's stock falls after lymphoma treatment trial data disappoints

Marketwatch

clinical trials

Flag link:

Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable

Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable

Forbes

cytokine release syndrome

Flag link:

Hemo-oncology newbie Bayer gears up for copanlisib launch

Hemo-oncology newbie Bayer gears up for copanlisib launch

Fierce Pharma

Flag link:

Two cancer drug prices have already been hiked by 8% this year

Two cancer drug prices have already been hiked by 8% this year

Marketwatch

Teva Pharmaceutical

Flag link:

Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep

Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep

Endpoints

clinical trials

Flag link:

Novartis' CAR-T stacks up to Kite in lymphoma

Novartis' CAR-T stacks up to Kite in lymphoma

BioPharma Dive

Flag link:

Celldex Cancer Drug Shows Good Early Data

Celldex Cancer Drug Shows Good Early Data

Investopedia

Celldex Therapeutics

Flag link:

Seattle Genetics moves up FDA timeline for cash cow drug Adcetris

Seattle Genetics moves up FDA timeline for cash cow drug Adcetris

Bizjournals.com

Seattle Genetics

Flag link:

Glimpse of promising lymphoma responses spurs a sharp spike in Epizyme shares

Glimpse of promising lymphoma responses spurs a sharp spike in Epizyme shares

Fierce Biotech

Flag link:

JNJ launches PhII lymphoma study for daratumumab

JNJ launches PhII lymphoma study for daratumumab

Fierce Biotech

non-Hodgkin's lymphoma

Flag link:

US FDA grants fast tract status to MorphoSys's MOR208 programme to treat DLBCL

US FDA grants fast tract status to MorphoSys's MOR208 programme to treat DLBCL

PharmaBiz

diffuse large B-cell lymphoma

Flag link:

Data on Celgene's Revlimid Published in Oncology Journal

Data on Celgene's Revlimid Published in Oncology Journal

Yahoo/Zacks

diffuse large B-cell lymphoma

Flag link:

ProNAi nabs $59.5M round to back PhII lymphoma drug

ProNAi nabs $59.5M round to back PhII lymphoma drug

Fierce Biotech

Flag link:

Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B-Cell Lymphoma and T-Cell Acute Lymphoblastic Leukemia Suggesting Broad Potential of IPI-145 in Blood Cancers

Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B-Cell Lymphoma and T-Cell Acute Lymphoblastic Leukemia Suggesting Broad Potential of IPI-145 in Blood Cancers

Yahoo/BusinessWire

large B-cell lymphoma

T-cell acute lymphoblastic leukemia

Infinity Pharmaceuticals

Flag link:

Seattle Genetics highlights ADCETRIS data at lymphoma conference

Seattle Genetics highlights ADCETRIS data at lymphoma conference

Yahoo/Fly on the Wall

Seattle Genetics

Flag link:

Celgene's Revlimid wins additional FDA lymphoma approval

Celgene's Revlimid wins additional FDA lymphoma approval

Reuters

mantle cell lymphoma

Flag link:

Eli Lilly's lymphoma drug fails in late-stage trial

Eli Lilly's lymphoma drug fails in late-stage trial

Reuters

Flag link:

Pages